Payment overview · 2025
General Payments
$533.63
25 reported records · 10 companies
Healthcare provider profile · identity verified
Jae H Pak, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Geriatric Psychiatry · SNELLVILLE, GA · NPI 1740280551
Verified facts
What the public records show
CMS Open Payments records show Jae H Pak, M.D. received $533.63 in general payments during 2025 across 25 reported records.
Neurocrine BioSciences, Inc. accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $118.92 | 22.3% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $79.81 | 15.0% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $78.79 | 14.8% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $78.67 | 14.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.11 | 9.4% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $34.28 | 6.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.35 | 6.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.43 | 4.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.85 | 3.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.42 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $533.63 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $118.92 | 5 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $78.79 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $78.67 | 4 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $55.82 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.11 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $41.50 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $38.31 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $34.28 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Quetiapine Fumarate | Quetiapine Fumarate | 880 | 307 |
| Donepezil Hcl | Donepezil Hcl | 628 | 251 |
| Clonazepam | Clonazepam | 601 | 137 |
| Lorazepam | Lorazepam | 515 | 170 |
| Alprazolam | Alprazolam | 511 | 92 |
| Trazodone Hcl | Trazodone Hcl | 435 | 186 |
| Memantine Hcl | Memantine Hcl | 420 | 137 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 374 | 151 |
| Citalopram Hbr | Citalopram Hydrobromide | 285 | 126 |
| Divalproex Sodium | Divalproex Sodium | 278 | 88 |
| Lamotrigine | Lamotrigine | 224 | 88 |
| Bupropion Xl | Bupropion Hcl | 214 | 74 |
| Mirtazapine | Mirtazapine | 210 | 74 |
| Olanzapine | Olanzapine | 210 | 72 |
| Gabapentin | Gabapentin | 191 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 186 | 118 |
| Zolpidem Tartrate | Zolpidem Tartrate | 175 | 46 |
| Temazepam | Temazepam | 161 | 38 |
| Risperidone | Risperidone | 157 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 133 | 85 |
| Sertraline Hcl | Sertraline Hcl | 129 | 60 |
| Aripiprazole | Aripiprazole | 119 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 41 |
| Oxcarbazepine | Oxcarbazepine | 109 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 85 | 57 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 82 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 81 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 50 |
| Benztropine Mesylate | Benztropine Mesylate | 77 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 73 | 30 |
| Lithium Carbonate | Lithium Carbonate | 72 | 19 |
| Methylphenidate Hcl | Methylphenidate Hcl | 67 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 28 |
| Diazepam | Diazepam | 58 | 13 |
| Losartan Potassium | Losartan Potassium | 56 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 30 |
| Eliquis | Apixaban | 52 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 51 | 36 |
| Lisinopril | Lisinopril | 48 | 28 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 46 | 16 |
| Potassium Chloride | Potassium Chloride | 46 | 29 |
| Carvedilol | Carvedilol | 40 | 28 |
| Rivastigmine | Rivastigmine | 40 | 13 |
| Metformin Hcl | Metformin Hcl | 36 | 28 |
| Omeprazole | Omeprazole | 36 | 24 |
| Levetiracetam | Levetiracetam | 35 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | 27 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | 15 |
| Famotidine | Famotidine | 33 | 16 |
| Furosemide | Furosemide | 33 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | 14 |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 21 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | 17 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 26 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 16 |
| Belsomra | Suvorexant | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Clozapine | Clozapine | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 18 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 16 | 13 |
| Glipizide | Glipizide | 16 | 12 |
| Invega Sustenna | Paliperidone Palmitate | 16 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Paliperidone Er | Paliperidone | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methylphenidate Er (La) | Methylphenidate Hcl | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | 11 |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $533.63 · 25 records | Neurocrine BioSciences, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AUSTEDO XR, Auvelity, COBENFY, FANAPT, HETLIOZ, INGREZZA, KISUNLA, Leqembi, NUPLAZID, REXULTI, UZEDY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error